Mingke Pharmaceutical: MRX-5 has obtained permission to conduct clinical trials in the United States.

Mingke Pharmaceuticals announces that its wholly-owned subsidiary, MicuRx Pharmaceuticals, Inc., has received notification from the US Food and Drug Administration (USFDA) that the clinical trial application for the company's independently developed antibacterial drug MRX-5 has been approved, allowing clinical trials to be conducted in the United States.